v3.25.4
Acquisitions and divestitures - Narrative (Details) - USD ($)
$ / shares in Units, $ in Millions
12 Months Ended
Dec. 26, 2025
Apr. 02, 2025
Oct. 08, 2024
Jul. 11, 2024
Jun. 20, 2024
May 31, 2024
Mar. 07, 2024
Dec. 28, 2025
Dec. 29, 2024
Dec. 31, 2023
Business Combination [Line Items]                    
Acquisitions, net of cash acquired (Note 18)               $ 17,541 $ 15,146 $ 0
Goodwill               48,772 44,200 36,558
Goodwill, related to acquisitions               3,488 8,209  
Acclarent                    
Business Combination [Line Items]                    
Proceeds from divestiture of brands                 300  
Ponvory                    
Business Combination [Line Items]                    
Proceeds from divestiture of brands                 200  
V-Wave Ltd.                    
Business Combination [Line Items]                    
Consideration transferred     $ 600              
IPR&D charge     500              
Yellow Jersey Therapeutics                    
Business Combination [Line Items]                    
Consideration transferred       $ 1,250            
IPR&D charge       $ 1,250            
Laminar                    
Business Combination [Line Items]                    
Consideration transferred                   400
IPR&D charge                   $ 400
Maximum | V-Wave Ltd.                    
Business Combination [Line Items]                    
Consideration transferred     $ 1,100              
Halda Therapeutics                    
Business Combination [Line Items]                    
Acquisitions, net of cash acquired (Note 18) $ 3,050                  
Acquisition related costs 200                  
Assets acquired including goodwill 3,400                  
Acquired in-process research and development 2,800                  
Goodwill 600                  
Liabilities assumed 600                  
Goodwill expected tax deductible, amount $ 0                  
Halda Therapeutics | HLD-0915                    
Business Combination [Line Items]                    
Discount rate 17.00%                  
Halda Therapeutics | HLD-0915 | Minimum                    
Business Combination [Line Items]                    
Probability of success factor 47.00%                  
Halda Therapeutics | HLD-0915 | Maximum                    
Business Combination [Line Items]                    
Probability of success factor 68.00%                  
Halda Therapeutics | HLD-0117                    
Business Combination [Line Items]                    
Discount rate 17.50%                  
Probability of success factor 17.00%                  
Intra-Cellular Therapies, Inc.                    
Business Combination [Line Items]                    
Acquisition related costs               400    
Other assets assumed   $ 17,500                
Acquired in-process research and development   8,300                
Goodwill   2,900                
Liabilities assumed   $ 3,000                
Probability of success factor   95.00%                
Acquisition price (in dollars per share)   $ 132.00                
Equity interests issued and issuable   $ 14,500                
Integration-related cost, expense   $ 100                
Intra-Cellular Therapies, Inc. | Minimum                    
Business Combination [Line Items]                    
Discount rate   11.50%                
Probability of success factor   34.00%                
Intra-Cellular Therapies, Inc. | Maximum                    
Business Combination [Line Items]                    
Discount rate   12.50%                
Probability of success factor   50.00%                
Ambrx                    
Business Combination [Line Items]                    
Acquisitions, net of cash acquired (Note 18)             $ 1,800      
Other assets assumed             2,300      
Acquired in-process research and development             1,900      
Liabilities assumed             500      
Goodwill, related to acquisitions             $ 300      
Proteologix                    
Business Combination [Line Items]                    
Acquisitions, net of cash acquired (Note 18)         $ 800          
Acquisition related costs               $ 0    
Other assets assumed         1,200          
Acquired in-process research and development         900          
Liabilities assumed         300          
Goodwill, related to acquisitions         $ 300          
Shockwave Medical, Inc.                    
Business Combination [Line Items]                    
Acquisitions, net of cash acquired (Note 18)           $ 11,500        
Acquisition related costs                 $ 900  
Other assets assumed           14,400        
Acquired in-process research and development           5,300        
Liabilities assumed           2,900        
Goodwill, related to acquisitions           7,600        
Acquired, inventory, current           500        
Acquired, other assets           400        
Payments to acquire businesses, gross           12,600        
Shockwave Medical, Inc. | In Process Research and Development                    
Business Combination [Line Items]                    
Identifiableintangible asset, indefinite-lived           $ 600